References:
1. Thijssen VLJL, Ausma J, Liu GS, Allessie MA, van Eys GJJM, Borgers M. Structural Changes of Atrial Myocardium During Chronic Atrial Fibrillation. Cardiovascular Pathology 2000; 9: 17–28.
2. Casaclang-Verzosa G, Gersh BJ, Tsang TSM. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol. 2008; 51: 1–11.
3. Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res. 2009; 2: 4.
4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50: e1-e88.
5. Waks JW, Josephson ME. Mechanisms of Atrial Fibrillation - Reentry, Rotors and Reality. Arrhythm Electrophysiol Rev. 2014; 3: 90–100.
6. Pellman J, Sheikh F. Atrial fibrillation: mechanisms, therapeutics, and future directions. Compr Physiol. 2015; 5: 649–665.
7. Rosso R, Kistler PM. Focal Atrial Tachycardia. Heart (British Cardiac Society) 2010; 96 :181-185.
8. Hari KJ, Nguyen TP, Soliman EZ. Relationship between P-wave duration and the risk of atrial fibrillation. Expert Rev Cardiovasc Ther. 2018; 16: 837–843.
9. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954–1968.
10. Shukla A, Curtis AB. Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression. Vasc Health Risk Manag. 2014; 10: 1–12.
11. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 123: e269-367.
12. D’Andrea A, De Corato G, Scarafile R, Romano S, Reigler L, Mita C, Allocca F, Limongelli G, Gigantino G, Liccardo B, Cuomo S, Tagliamonte G, Caso P, Calbrò R. Left atrial myocardial function in either physiological or pathological left ventricular hypertrophy: a two-dimensional speckle strain study. Br J Sports Med. 2008; 42: 696-702.
13. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008; 1: 62-73.
14. Censi F, Calcagnini G, Triventi M, Mattei E, Bartolini P, Corazza I, Boriani G. P-wave characteristics after electrical external cardioversion: predictive indexes of relapse. Conf Proc IEEE Eng Med Biol Soc. 2010: 3442-3445.
15. Bagliani G, Michelucci A, Angeli F, Meniconi L. Atrial activation analysis by surface P wave and multipolar esophageal recording after cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol. 2003; 26: 1178-1188.
16. Sato T, Mitamura H, Kurita Y, Takeshita A, Shinagawa K, Miyoshi S, Kanki H, Hara M, Takatsuki S, Soejima K, Ogawa S. Recovery of electrophysiological parameters after conversion of atrial fibrillation. Int J Cardiol. 2001; 79: 183-189.
17. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011; 108: 56‐62.
18. Wang, A., Green, J. B., Halperin, J. L., & Piccini, J. P. (2019). Atrial Fibrillation and Diabetes Mellitus. Journal of the American College of Cardiology 2019; 74: 1107–1115.
19. Fu H, Liu C, Li J, et al. Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiol J. 2013; 20: 59-67.
20. Li B, Pan Y, Li X. Type 2 Diabetes Induces Prolonged P-wave Duration without Left Atrial Enlargement. J Korean Med Sci. 2016; 31: 525-534.
21. Ayhan S, Ozturk S, Alcelik A, et al. Atrial conduction time and atrial mechanical function in patients with impaired fasting glucose. J Interv Card Electrophysiol. 2012; 35: 247-252.
22. Huang J-C, Wei S-Y, Chen S-C, et al. P Wave Dispersion and Maximum P Wave Duration Are Associated with Renal Outcomes in Chronic Kidney Disease. PLoS One 2014; 9
23. Su H-M, Tsai W-C, Lin T-H, et al. P Wave Dispersion and Maximum P Wave Duration Are Independently Associated with Rapid Renal Function Decline. PLoS One 2012; 7
24. Burashnikov A, Di Diego JM, Sicouri S, Ferreiro M, Carlsson L, Antzelevitch C. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm. 2008; 5: 1735-1742.
25. Sasaki N, Watanabe I, Kogawa R, Sonoda K, Takahashi K, Okumura Y, Ohkubo K, Nakai T, Hirayama A. Effects of intravenous amiodarone and ibutilide on action potential duration and atrial conduction kinetics in patients with persistent atrial fibrillation. Int Heart J. 2014; 55 : 244-248.
26. Cheriex EC, Krijne R, Brugada P, Heymeriks J, Wellens HJ. Lack of clinically significant beta-blocking effect of propafenone. Eur Heart J. 1986; 8: 53-56.
27. Aytemir K, Aksoyek S, Yildirir A, Ozer N, Oto A. Prediction of atrial fibrillation recurrence after cardioversion by P wave signal-averaged electrocardiography. Int J Cardiol. 1999; 70: 15-21.
28. Perzanowski C, Ho AT, Jacobson AK. Increased P-wave dispersion predicts recurrent atrial fibrillation after cardioversion. J Electrocardiol. 2005; 38: 43-46.
29. Gonna H, Gallagher MM, Guo XH, Yap YG, Hnatkova K, Camm AJ. P-wave abnormality predicts recurrence of atrial fibrillation after electrical cardioversion: a prospective study. Ann Noninvasive Electrocardiol. 2014; 19: 57-62.
30. Zimmer K, Przywara W, Zyśko D, Sławuta A, Gajek J. The nature of P-wave dispersion - A clinically useful parameter that does not exist. Int J Cardiol. 2016; 212: 59-60.